Masudopeptide is the world's first approved glucagon/glucagon-like peptide-1 dual receptor agonist. It suppresses appetite and promotes insulin secretion by activating the GLP-1 receptor, while activating the GCG receptor to increase energy consumption and fat decomposition, especially significantly improving liver fat metabolism.